FDA calls Amgen promo 'misleading'; Shire's Vyvanse, et al, outdo Adderall;

> The FDA said Wednesday that an Amgen advertising brochure for Sensipar, a drug used in certain kidney disease patients, is "false and misleading." Report

> For the first time in over five years, combined sales of Shire's newest drugs overtook Adderall XR, its top-selling attention deficit disorder (ADHD) drug. Report

> GlaxoSmithKline will acquire Genelabs Technologies for $57 million. The company said the deal will strengthen Glaxo's effort to develop treatments for the hepatitis C virus. Report

> A new vaccine that targets rotavirus is being credited as a remarkable success. A slate of studies say that RotaTeq has sliced the number of new cases by anywhere from 66 percent to 100 percent. Report

> Physicians have long known that the elderly often fail to generate the kind of immune response they need when given a standard flu shot. Now a research group says that quadrupling their vaccine dose can result in 30 percent to 80 percent more antibodies--the kind of response that they need to guard against the flu. Report

> Allergan said Wednesday its profit grew 8 percent in the third quarter, as sales of specialty drugs and medical devices both increased. Report

> IndiPharm has appointed Robert R. Hughes as Vice President of Sales and Marketing to lead the company's global sales and marketing efforts. Release

> Montreal drug developer Theratechnologies has licensed EMD Serono, an affiliate of Europe's Merck KGaA, to commercialize tesamorelin in the U.S. on an exclusive basis. Report 

> The Hungarian pharmaceutical market could attain the value of 2.4 billion euros in 2010, at an average growth rate of 9.5 percent, according to estimations of Polish market research company PMR, specialized in the Central and Eastern European region. Report

> Biovest International said it has a distribution agreement to supply its personalized cancer vaccine, BiovaxID, in parts of Europe under a named-patient program, with sales expected to start in the first quarter of 2009. Report 

> Hot flashes, night sweats and joint symptoms in breast cancer patients getting endocrine treatment are signs of estrogen depletion or blockage and may point to successful treatment, British researchers report. Report

> With the public markets closed and venture capital slowing, biotechs are taking steps to make their cash reserves last as long as possible. In order to survive, many biotechs are cutting costs by axing staff and halting all but their most advanced programs. Report

> Merck Serono has signed a deal to license the U.S. commercialization right to tesamorelin, a drug to treat excess abdominal fat in HIV patients with lipodystrophy. Report

> Shares of South San Francisco-based Rigel dropped 38 percent Monday after the company reported Phase IIa results of arthritis drug R788. Report

And Finally ... Turning your clock back on Sunday may be good for your heart. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.